Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass

Eur J Cardiothorac Surg. 2011 Feb;39(2):248-55. doi: 10.1016/j.ejcts.2010.05.025. Epub 2010 Jun 29.

Abstract

Objective: Activation of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway can induce potent cardioprotection-like effects against ischaemia-reperfusion injury and nitro-oxidative stress. We investigated the effects of pharmacological pre-conditioning with Cinaciguat (BAY 58-2667), a novel sGC activator on peroxynitrite-induced endothelial dysfunction in vitro, as well as on myocardial and coronary vascular function during reperfusion in a canine model of cardioplegic arrest and extracorporeal circulation.

Methods: Isolated coronary arterial rings exposed to peroxynitrite were investigated for vasomotor function. Vehicle- and Cinaciguat-pre-treated (8.33 μg h(-1) or 25 μg h(-1) intravenous (IV) for 30 min) anaesthetised dogs (n = 6-7 per group) underwent hypothermic cardiopulmonary bypass with 60 min of hypothermic cardioplegic arrest. Left- and right-ventricular end-systolic pressure-volume relationship (ESPVR) was measured by a pressure-volume conductance catheter at baseline and after 60 min of reperfusion. Coronary blood flow, vasodilatation to acetylcholine and myocardial level of adenosine triphosphate were determined.

Results: Pre-incubation of coronary rings with Cinaciguat improved peroxynitrite-induced endothelial dysfunction. Compared with control, pharmacological pre-conditioning with Cinaciguat (25 μg h(-1)) led to higher myocardial adenosine triphosphate content, to a better recovery of left- and right-ventricular contractility (Δ slope of left ventricular ESPVR given as percent of baseline: 102.4 ± 19.1% vs 56.0 ± 7.1%) and to a higher coronary blood flow (49.6 ± 3.5 ml min(-1) vs 28.0 ± 3.9 ml min(-1)). Endothelium-dependent vasodilatation to acetylcholine was improved in the treatment groups.

Conclusions: Pre-conditioning with Cinaciguat improves myocardial and endothelial function after cardiopulmonary bypass with hypothermic cardiac arrest. The observed protective effects imply that pharmacological sGC activation could be a novel therapeutic option in the protection against ischaemia-reperfusion injury in cardiac surgery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoates / pharmacology
  • Benzoates / therapeutic use*
  • Cardiopulmonary Bypass / adverse effects*
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Disease Models, Animal
  • Dogs
  • Drug Evaluation, Preclinical
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology
  • Enzyme Activation
  • Female
  • Guanylate Cyclase / metabolism
  • Hemodynamics / drug effects
  • Male
  • Oxidative Stress / drug effects
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Reperfusion Injury / enzymology
  • Reperfusion Injury / etiology
  • Reperfusion Injury / prevention & control*
  • Soluble Guanylyl Cyclase
  • Tissue Culture Techniques
  • Vasomotor System / drug effects
  • Vasomotor System / physiopathology
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Right / drug effects

Substances

  • Benzoates
  • Cardiotonic Agents
  • Receptors, Cytoplasmic and Nuclear
  • BAY 58-2667
  • Guanylate Cyclase
  • Soluble Guanylyl Cyclase